Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,369 active trials118 approved drugs1,149 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,729 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,405)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03069508 | Clemizole HCl for Subjects With Hepatocellular Carcinoma | unknown | Phase 2 | 12 | Eiger Group International, Inc.INDUSTRY | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01980472 | Chemotherapy Plus Bevacizumab in Elderly Non-small Cell Lung Cancer Patients | unknown | Phase 2 | 50 | Grupo de Investigación y Divulgación OncológicaOTHER | 1 | Feb 27, 2017 | clinicaltrials |
| NCT02956772 | Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients | unknown | Phase 2 | 190 | Hunan Provincial People's HospitalOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT03058432 | Concurrent Chemotherapy for Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 122 | Zhejiang Cancer HospitalOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT01755013 | Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma | unknown | Phase 2 / Phase 3 | 55 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT02974933 | Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer | unknown | Phase 2 | 48 | Wuling OuOTHER | 1 | Feb 17, 2017 | clinicaltrials |
| NCT03053856 | Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients | unknown | Phase 2 | 37 | Samsung Medical CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT03050437 | A Study Comparing Pemetrexed Plus Cisplatin Versus Pemetrexed Alone in NSCLC Patients Who Have Progressed on First Line EGFR-TKI | unknown | Phase 2 | 96 | Samsung Medical CenterOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT03047525 | Study of DC-CTL Combined With CIK for Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 200 | Xiaoyi HuangOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT03046979 | Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC)(HCC) | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 8, 2017 | clinicaltrials |
| NCT01714908 | Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21(RECEL) | unknown | Phase 2 | 100 | Jinming YuOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT01744925 | Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT02370017 | Combined Effect of Natural Killer Cell and Doublet Chemotherapy in Advanced NSCLC as the 1st Line Treatment(ANKL-2) | unknown | Phase 2 | 68 | The Catholic University of KoreaOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT02446795 | Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial(QUASAR) | unknown | Phase 1 / Phase 2 | 104 | Consorzio OncotechOTHER | 1 | Jan 18, 2017 | clinicaltrials |
| NCT02878889 | A Phase II Trial of S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma. | unknown | Phase 2 | 53 | Zhejiang Cancer HospitalOTHER | 1 | Jan 11, 2017 | clinicaltrials |
| NCT03013712 | A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer(CARTEPC) | unknown | Phase 1 / Phase 2 | 60 | First Affiliated Hospital of Chengdu Medical CollegeOTHER | 1 | Jan 6, 2017 | clinicaltrials |
| NCT03006588 | EUS-FNA for Retropharyngeal Lymph Node (RPLN) in Recurrent Nasopharyngeal Carcinoma (NPC) Patients | unknown | Phase 2 / Phase 3 | 100 | Sun Yat-sen UniversityOTHER | 1 | Jan 2, 2017 | clinicaltrials |
| NCT02987699 | Phase II Study of HAIC Using Cisplatin,Leucovorin and 5-Fluorouracil | unknown | Phase 2 | 54 | Sun Yat-sen UniversityOTHER | 1 | Dec 28, 2016 | clinicaltrials |
| NCT03002844 | EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism | unknown | Phase 2 | 50 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Dec 28, 2016 | clinicaltrials |
| NCT02029209 | To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer | unknown | Phase 2 / Phase 3 | 110 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 16, 2016 | clinicaltrials |
| NCT02985255 | Role of Neo-adjuvant Chemotherapy in Tongue Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue | unknown | Phase 2 | 30 | HealthCare Global Enterprise Ltd.INDUSTRY | 1 | Dec 7, 2016 | clinicaltrials |
| NCT02617134 | CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor | unknown | Phase 1 / Phase 2 | 20 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02839954 | CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02587689 | Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 20 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 5, 2016 | clinicaltrials |
| NCT02980809 | Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer | unknown | Phase 2 | 60 | First Hospitals affiliated to the China PLA General HospitalOTHER_GOV | 0 | Dec 2, 2016 | clinicaltrials |
| NCT01504997 | Phase II Study for Robot Assisted Distal Gastrectomy(RADGphaseII) | unknown | Phase 2 | 23 | Shizuoka Cancer CenterOTHER | 1 | Nov 29, 2016 | clinicaltrials |
| NCT02975609 | Phase II Trial of SBRT Compared With Conventional Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer | unknown | Phase 2 | 100 | Shanghai Chest HospitalOTHER | 1 | Nov 29, 2016 | clinicaltrials |
| NCT02787447 | Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy | unknown | Phase 2 | 46 | First People's Hospital of HangzhouOTHER | 1 | Nov 25, 2016 | clinicaltrials |
| NCT02787473 | A Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Docetaxel Consolidation in Patients With Inoperable Squamous Cell Lung Cancer | unknown | Phase 2 | 54 | First People's Hospital of HangzhouOTHER | 1 | Nov 25, 2016 | clinicaltrials |
| NCT02274337 | Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Nov 23, 2016 | clinicaltrials |
| NCT02972320 | Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic | unknown | Phase 2 | 60 | Yunpeng LiuOTHER | 1 | Nov 23, 2016 | clinicaltrials |
| NCT02755675 | uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung | unknown | Phase 2 | 120 | Rigshospitalet, DenmarkOTHER | 1 | Nov 21, 2016 | clinicaltrials |
| NCT02333890 | A Phase 2 Randomized, Double-blind Trial Evaluating the Effects of Chloroquine in Breast Cancer(CUBiC) | unknown | Phase 2 | 60 | Ottawa Hospital Research InstituteOTHER | 1 | Nov 18, 2016 | clinicaltrials |
| NCT02960607 | High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC | unknown | Phase 2 | 25 | Chinese Academy of Medical SciencesOTHER | 1 | Nov 18, 2016 | clinicaltrials |
| NCT02923557 | Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinoma Patients | unknown | Phase 2 | 200 | Peking University First HospitalOTHER | 1 | Nov 17, 2016 | clinicaltrials |
| NCT02961270 | Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation | unknown | Phase 2 | 30 | Chinese Academy of Medical SciencesOTHER | 1 | Nov 11, 2016 | clinicaltrials |
| NCT02871518 | Two Cycles Versus Three Cyclle of CCRT for Low Risk Locoregionally Advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 236 | Sun Yat-sen UniversityOTHER | 1 | Nov 10, 2016 | clinicaltrials |
| NCT02960724 | uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer | unknown | Phase 2 | 90 | Rigshospitalet, DenmarkOTHER | 1 | Nov 10, 2016 | clinicaltrials |
| NCT02959151 | A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy | unknown | Phase 1 / Phase 2 | 20 | Shanghai GeneChem Co., Ltd.INDUSTRY | 1 | Nov 8, 2016 | clinicaltrials |
| NCT02951637 | Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial | unknown | Phase 2 | 300 | Shanghai Chest HospitalOTHER | 0 | Nov 1, 2016 | clinicaltrials |
| NCT02943798 | Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma | unknown | Phase 2 | 118 | Shanghai Chest HospitalOTHER | 0 | Oct 25, 2016 | clinicaltrials |
| NCT01683175 | Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation | unknown | Phase 2 | 94 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 20, 2016 | clinicaltrials |
| NCT02421640 | Phase II Trial of TIL Following CCRT in Patients With Locoregionally Advanced NPC(TIL) | unknown | Phase 2 | 116 | Sun Yat-sen UniversityOTHER | 1 | Oct 18, 2016 | clinicaltrials |
| NCT02935023 | Carbon Ion Radiotherapy in Treating Patients Undergoing Systemic Therapy for Oligo-metastatic Prostate Cancer | unknown | Phase 2 | 47 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Oct 17, 2016 | clinicaltrials |
| NCT02930954 | Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance | unknown | Phase 2 | 180 | Caicun ZhouOTHER | 1 | Oct 13, 2016 | clinicaltrials |
| NCT02906384 | Memory and MRI Changes With Hippocampus Avoidance Prophylactic Cranial Irradiation(HA-PCI) for Small Cell Lung Cancer(SCLC) | unknown | Phase 2 | 154 | Zhejiang Cancer HospitalOTHER | 1 | Oct 10, 2016 | clinicaltrials |
| NCT01771289 | Neoadjuvant Concurrent Chemoradiation With Weekly Docetaxel/Cisplatin for Resectable IIIA-N2 NSCLC | unknown | Phase 2 | 50 | Peking University People's HospitalOTHER | 1 | Sep 27, 2016 | clinicaltrials |
| NCT02244502 | Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE) | unknown | Phase 1 / Phase 2 | 31 | NovoCure Ltd.INDUSTRY | 4 | Sep 21, 2016 | clinicaltrials |
| NCT02906150 | Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type | unknown | Phase 2 | 140 | SciClone PharmaceuticalsINDUSTRY | 1 | Sep 19, 2016 | clinicaltrials |
| NCT02906163 | First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy | unknown | Phase 1 / Phase 2 | 188 | SciClone PharmaceuticalsINDUSTRY | 1 | Sep 19, 2016 | clinicaltrials |
Data updated 24 days agoSource updated Mar 3, 2017source: clinicaltrials